A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.Giuseppe Giaccone, Herbert M. Pinedo, Cornelis J. A. Punt et al.|PubMed|2002Cited by 507
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, James Larkin et al.|The Lancet Oncology|2021Cited by 389
Circulating Vα24+ Vβ11+ NKT Cell Numbers Are Decreased in a Wide Variety of Diseases That Are Characterized by Autoreactive Tissue DamageHerbert M. Pinedo, B. Mary E. von Blomberg, Nobusuke Nishi et al.|Clinical Immunology|2001Cited by 270
Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor ResponseAstrid A.M. van der Veldt, Epie Boven, Martijn R. Meijerink et al.|Clinical Cancer Research|2008Cited by 170
Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinibAstrid A.M. van der Veldt, Epie Boven, Martijn R. Meijerink et al.|British Journal of Cancer|2010Cited by 151